In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
Fierce Biotech
|
June 26, 2026
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
For anyone watching the GLP-1 headlines in recent years, it’s not hard to see which way the wind is blowing…
For more
Clinical Leader
|
June 9, 2026
New Primary Endpoint For Tetraplegia Drug Gets Support From Patients And The FDA
A conversation between NervGen CEO Adam Rogers and Clinical Leader Executive Editor Abby Proch. Spinal cord injury (SCI) has no…
For more
The Scientist
|
June 4, 2026
A New Approach to Treating Respiratory Attacks
Barry Quart from Connect Biopharma discusses the company’s dual-cytokine–targeting biologic that aims to treat acute asthma, chronic obstructive pulmonary disease…
For more
Fierce Pharma
|
June 3, 2026
Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the…
For more
GEN News
|
June 1, 2026
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives
First patient dosed in Phase II AMETHYST trial days after Sobi announces positive Phase III data for pozdeutinurad, which like…
For more
Fierce Pharma
|
May 29, 2026
After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 lung cancer market,…
For more
Longevity.Technology
|
May 19, 2026
‘Rebuilding the human immune system is possible’
As immunosenescence drives systemic disease, banked bone marrow could scale from a transplant tool into healthspan infrastructure. Bone marrow transplantation…
For more
South Florida Business Journal
|
May 8, 2026
European company to acquire Miami pharma business for $4.1 billion
The deal is part of a wider trend of acquisitions in this emerging industry….
For more
Bloomberg
|
May 7, 2026
Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build…
For more
The Bio Report
|
May 6, 2026
Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
